Lipocine (LPCN) Non Operating Income (2017 - 2025)
Lipocine's (LPCN) quarterly Non Operating Income came in at $174208.0 in Q3 2025, down 57.68% YoY from $411655.0 in Q3 2024, and down 12.3% on a QoQ basis from $198637.0 in Q2 2025.
Lipocine (LPCN) Non Operating Income (2017 - 2025) Analysis & Trends
Lipocine (LPCN) has 6 years of Non Operating Income data on file, last reported at $174208.0 in Q3 2025.
- Quarterly Non Operating Income fell 57.68% year-over-year to $174208.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $835060.0 (down 32.6% YoY) and the FY2024 annual result came in at $1.2 million, down 26.31% from the prior year.
- Non Operating Income slipped to $174208.0 in Q3 2025, from $198637.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $895754.0 in Q2 2022 to a low of $174208.0 in Q3 2025.
- A 4-year average of $361386.5 and a median of $321527.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income rose 4.91% — and 2025, when it tumbled 57.68%.
- Tracing LPCN's Non Operating Income over 4 years: stood at $331401.0 in 2022, then retreated by 5.96% to $311653.0 in 2023, then dropped by 24.05% to $236704.0 in 2024, then slipped by 26.4% to $174208.0 in 2025.
- The last three Non Operating Income figures came in at $174208.0 (Q3 2025), $198637.0 (Q2 2025), and $225511.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 174,208.00 |
| Jun 30, 2025 | 198,637.00 |
| Mar 31, 2025 | 225,511.00 |
| Dec 31, 2024 | 236,704.00 |
| Sep 30, 2024 | 411,655.00 |
| Jun 30, 2024 | 224,415.00 |
| Mar 31, 2024 | 291,292.00 |
| Dec 31, 2023 | 311,653.00 |
| Sep 30, 2023 | 392,396.00 |
| Jun 30, 2023 | 406,976.00 |
| Mar 31, 2023 | 468,603.00 |
| Dec 31, 2022 | 331,401.00 |
| Sep 30, 2022 | 490,206.00 |
| Jun 30, 2022 | 895,754.00 |
| Sep 30, 2018 | -106,016.00 |
| Jun 30, 2018 | -91,091.00 |
| Mar 31, 2018 | -82,285.00 |
| Sep 30, 2017 | 65,811.00 |
| Jun 30, 2017 | 50,852.00 |
| Mar 31, 2017 | 48,355.00 |